Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study-Reference-Cited by-同舟云学术

Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study

Published:2021-09 Issue: Volume:155 Page:136-144
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Boyle Jemma M.^ORCID,Hegarty Gemma^ORCID,Frampton Christopher,Harvey-Jones Elizabeth,Dodkins Joanna,Beyer Katharina,George Gincy^ORCID,Sullivan Richard,Booth Christopher,Aggarwal Ajay

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. The use of real-world data in cancer drug development;Skovlund;Eur J Canc,2018

2. Real-world evidence – what is it and what can it tell us?;Sherman;N Engl J Med,2016

3. Real-world data: towards achieving the achievable in cancer care;Booth;Nat Rev Clin Oncol,2019

4. Real-world evidence and regulatory drug approval;Raphael;Nat Rev Clin Oncol,2020

5. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report;Garrison;Value Health,2007

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of involuntary treatment among community-living older persons with dementia: A systematic review;Archives of Gerontology and Geriatrics;2024-12

2. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10

3. Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs;JAMA;2024-06-25

4. Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022);ESMO Real World Data and Digital Oncology;2024-06

5. Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries;Future Oncology;2024-04-25